Gail L Brown

Summary

Publications

  1. ncbi Oral ezatiostat HCl (Telintra®, TLK199) and idiopathic chronic neutropenia (ICN): a case report of complete response of a patient with G-CSF resistant ICN following treatment with ezatiostat, a glutathione S-transferase P1-1 (GSTP1-1) inhibitor
    Roger M Lyons
    Cancer Care Centers of South Texas, US Oncology, San Antonio, TX 78229, USA
    J Hematol Oncol 4:43. 2011
  2. ncbi Phase 1-2a multicenter dose-escalation study of ezatiostat hydrochloride liposomes for injection (Telintra, TLK199), a novel glutathione analog prodrug in patients with myelodysplastic syndrome
    Azra Raza
    University of Massachusetts Medical Center, Worcester, MA, USA
    J Hematol Oncol 2:20. 2009
  3. ncbi Phase 2 study of canfosfamide in combination with pegylated liposomal doxorubicin in platinum and paclitaxel refractory or resistant epithelial ovarian cancer
    John J Kavanagh
    Telik, Inc, Palo Alto, CA, USA
    J Hematol Oncol 3:9. 2010

Collaborators

  • John J Kavanagh
  • Roger M Lyons
  • Azra Raza
  • Shelby Young
  • Sharon T Wilks
  • Peter Emanuel
  • Howard Burris
  • Naomi Galili
  • Peter Curtin
  • James G Keck
  • Natalie Callander
  • Stefan Faderl
  • Zeev Estrov
  • Marsha Jones
  • Stephanie Williams
  • Lawrence Piro
  • Lisa Meng
  • Richard A Larson
  • Leonel Ochoa

Detail Information

Publications3

  1. ncbi Oral ezatiostat HCl (Telintra®, TLK199) and idiopathic chronic neutropenia (ICN): a case report of complete response of a patient with G-CSF resistant ICN following treatment with ezatiostat, a glutathione S-transferase P1-1 (GSTP1-1) inhibitor
    Roger M Lyons
    Cancer Care Centers of South Texas, US Oncology, San Antonio, TX 78229, USA
    J Hematol Oncol 4:43. 2011
    ..These results suggest potential roles for ezatiostat in the treatment of patients with ICN who are not responsive to G-CSF, as an oral therapy alternative, or as an adjunct to G-CSF, and further studies are warranted...
  2. ncbi Phase 1-2a multicenter dose-escalation study of ezatiostat hydrochloride liposomes for injection (Telintra, TLK199), a novel glutathione analog prodrug in patients with myelodysplastic syndrome
    Azra Raza
    University of Massachusetts Medical Center, Worcester, MA, USA
    J Hematol Oncol 2:20. 2009
    ..In phase 2, ezatiostat was administered on 2 dose schedules: 600 mg/m2 IV on days 1 to 5 or days 1 to 3 of a 21-day treatment cycle...
  3. ncbi Phase 2 study of canfosfamide in combination with pegylated liposomal doxorubicin in platinum and paclitaxel refractory or resistant epithelial ovarian cancer
    John J Kavanagh
    Telik, Inc, Palo Alto, CA, USA
    J Hematol Oncol 3:9. 2010
    ..The primary endpoints were objective response rate (ORR) and progression-free survival (PFS)...